Search

Your search keyword '"Richardson, Paul G."' showing total 96 results
Start Over Author "Richardson, Paul G." Publisher american society of clinical oncology (asco)
96 results on '"Richardson, Paul G."'

2. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Author

Dimopoulos, Meletios A., primary, Oriol, Albert, additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Bahlis, Nizar J., additional, Usmani, Saad Z., additional, Rabin, Neil, additional, Orlowski, Robert Z., additional, Suzuki, Kenshi, additional, Plesner, Torben, additional, Yoon, Sung-Soo, additional, Ben Yehuda, Dina, additional, Richardson, Paul G., additional, Goldschmidt, Hartmut, additional, Reece, Donna, additional, Ahmadi, Tahamtan, additional, Qin, Xiang, additional, Garvin Mayo, Wendy, additional, Gai, Xue, additional, Carey, Jodi, additional, Carson, Robin, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

3. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Author

Dimopoulos, Meletios A., primary, Dytfeld, Dominik, additional, Grosicki, Sebastian, additional, Moreau, Philippe, additional, Takezako, Naoki, additional, Hori, Mitsuo, additional, Leleu, Xavier, additional, LeBlanc, Richard, additional, Suzuki, Kenshi, additional, Raab, Marc S., additional, Richardson, Paul G., additional, Popa McKiver, Mihaela, additional, Jou, Ying-Ming, additional, Yao, David, additional, Das, Prianka, additional, and San-Miguel, Jesús, additional

Published
2023
Full Text
View/download PDF

4. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.

Author

Richardson, Paul G., primary, Jacobus, Susanna J., additional, Weller, Edie, additional, Hassoun, Hani, additional, Lonial, Sagar, additional, Raje, Noopur S., additional, Medvedova, Eva, additional, McCarthy, Philip L., additional, Libby, Edward N., additional, Voorhees, Peter M., additional, Orlowski, Robert Z., additional, Anderson, Larry D., additional, Hurd, David D., additional, Pasquini, Marcelo C., additional, Masone, Kelly, additional, Moreau, Philippe, additional, Avet-Loiseau, Herve, additional, Attal, Michel, additional, Anderson, Kenneth Carl, additional, and Munshi, Nikhil C., additional

Published
2022
Full Text
View/download PDF

5. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.

Author

Lonial, Sagar, primary, Grosicki, Sebastian, additional, Hus, Marek, additional, Song, Kevin W., additional, Facon, Thierry, additional, Callander, Natalie Scott, additional, Ribrag, Vincent, additional, Uttervall, Katarina, additional, Quach, Hang, additional, Vorobyev, Vladimir I., additional, Min, Chang Ki, additional, Cheng, Shinta, additional, Smith, L. Mary, additional, Yu, Jing, additional, Collingwood, Therese, additional, Holkova, Beata, additional, Kremer, Brandon, additional, Gupta, Ira, additional, Richardson, Paul G., additional, and Minnema, Monique C., additional

Published
2022
Full Text
View/download PDF

6. B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.

Author

Nadeem, Omar, primary, Redd, Robert, additional, Mo, Clifton Craig, additional, Laubach, Jacob, additional, Prescott, Julia, additional, Metivier, Amada, additional, Davie, Christine, additional, Bertoni, Meredith, additional, Murphy, Elizabeth, additional, Sheehan, Brian, additional, Tague, Kelsey, additional, Shrestha, Hira, additional, Medina, Rebekah, additional, Distaso, Alexandra, additional, Leblebjian, Houry, additional, Richardson, Paul G., additional, and Ghobrial, Irene M., additional

Published
2022
Full Text
View/download PDF

7. A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.

Author

Yee, Andrew J, primary, Nadeem, Omar, additional, Rosenblatt, Jacalyn, additional, Bianchi, Giada, additional, O'Donnell, Elizabeth, additional, Branagan, Andrew R., additional, Harrington, Cynthia C., additional, Agyemang, Emerentia A., additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Packer, Lisette A., additional, Bernstein, Zachary S., additional, Lyons, Rebecca T., additional, Riadi, Manal, additional, Rowell, Sean M., additional, McVey, Cailin, additional, Goguen, Amy C., additional, Horick, Nora K., additional, Richardson, Paul G., additional, and Raje, Noopur S., additional

Published
2022
Full Text
View/download PDF

8. Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

Author

Rodriguez, Cesar, primary, Kaufman, Jonathan L., additional, Laubach, Jacob, additional, Sborov, Douglas W., additional, Reeves, Brandi, additional, Chari, Ajai, additional, Silbermann, Rebecca Wang, additional, Costa, Luciano J., additional, Anderson, Larry D., additional, Nathwani, Nitya, additional, Shah, Nina, additional, Bumma, Naresh, additional, Jakubowiak, Andrzej J., additional, Orlowski, Robert Z., additional, Pei, Huiling, additional, Cortoos, Annelore, additional, Patel, Sharmila, additional, Lin, Thomas S., additional, Richardson, Paul G., additional, and Voorhees, Peter M., additional

Published
2022
Full Text
View/download PDF

9. Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Author

Usmani, Saad Zafar, primary, Hoering, Antje, additional, Ailawadhi, Sikander, additional, Sexton, Rachael, additional, Lipe, Brea, additional, Valent, Jason Neil, additional, Rosenzweig, Michael Alan, additional, Zonder, Jeffrey A., additional, Dhodapkar, Madhav V., additional, Callander, Natalie Scott, additional, Zimmerman, Todd M., additional, Voorhees, Peter M., additional, Durie, Brian G., additional, Rajkumar, S. Vincent, additional, Richardson, Paul G., additional, and Orlowski, Robert Z., additional

Published
2022
Full Text
View/download PDF

11. Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty.

Author

Oriol Rocafiguera, Albert, primary, Dimopoulos, Meletios A., additional, Schjesvold, Fredrik, additional, Beksac, Meral, additional, Yagci, Münci, additional, Larocca, Alessandra, additional, Guo, Shien, additional, Mu, Yutian, additional, Hong, Kevin, additional, Dhanasiri, Sujith, additional, Richardson, Paul G., additional, and Weisel, Katja, additional

Published
2022
Full Text
View/download PDF

13. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Author

Richardson, Paul G., primary, Kumar, Shaji K., additional, Masszi, Tamás, additional, Grzasko, Norbert, additional, Bahlis, Nizar J., additional, Hansson, Markus, additional, Pour, Luděk, additional, Sandhu, Irwindeep, additional, Ganly, Peter, additional, Baker, Bartrum W., additional, Jackson, Sharon R., additional, Stoppa, Anne-Marie, additional, Gimsing, Peter, additional, Garderet, Laurent, additional, Touzeau, Cyrille, additional, Buadi, Francis K., additional, Laubach, Jacob P., additional, Cavo, Michele, additional, Darif, Mohamed, additional, Labotka, Richard, additional, Berg, Deborah, additional, and Moreau, Philippe, additional

Published
2021
Full Text
View/download PDF

14. Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211)

Author

Saad Usmani, Hoering, Antje, Ailawadhi, Sikander, Sexton, Rachael, Lipe, Brea, Valent, Jason Neil, Rosenzweig, Michael Alan, Zonder, Jeffrey A., Dhodapkar, Madhav V., Callander, Natalie Scott, Zimmerman, Todd M., Voorhees, Peter M., Durie, Brian G., Rajkumar, S. Vincent, Richardson, Paul G., and Orlowski, Robert Z.

Subjects
Cancer Research, Oncology
Abstract

8054 Background: The introduction of immunomodulatory agents, proteasome inhibitors, and autologous stem cell transplantation (ASCT) has improved outcomes for patients with multiple myeloma (MM), but those with high risk MM (HRMM) have a poor long-term prognosis. Herein we provide survival outcomes on the first randomized trial in newly diagnosed HRMM, S1211, to follow-up on the previously reported progression-free survival (PFS) (NCT01668719, Usmani SZ et al, Lancet Haem 2021). Methods: S1211 is a randomized phase II trial comparing 8 cycles of lenalidomide, bortezomib and dexamethasone (RVd) induction followed by dose-attenuated RVd maintenance until disease progression with or without elotuzumab (RVd-Elo). Stem cell collection was allowed, but ASCT was deferred until progression. HRMM was defined by one of the following: gene expression profiling high-risk (GEPhi), t(14;16), t(14;20), del(17p), amplification 1q21, primary plasma cell leukemia (pPCL), or elevated serum LDH (> 2X ULN). Median PFS was the primary endpoint, using a one-sided stratified log-rank test at a one-sided significance level of 0.1. Secondary endpoints included overall response rate (ORR), adverse events (AE), serious adverse events (SAE) and OS. Response was assessed using the IMWG 2009 criteria. Results: S1211 enrolled 103 evaluable patients, RVd n=54, RVd-Elo n=49. 74% had ISS II/III, 48% amp1q21, 38% del(17p), 11% t(14;16), 9% GEPhi, 7% pPCL, 5% t(14;20) and 4% elevated LDH (17% >1 feature). With median follow-up of 72 months (mos.), no difference in median PFS was observed [RVd-Elo=29 mos., RVd= 34 mos., HR = 1.11 (80% CI=0.82, 1.49, p=0.66]. No difference in OS was observed [RVd-Elo = median not reached (NR), RVd= 68 mos., HR = 0.85 (80% CI: 0.59, 1.23), p-value = 0.58]. 76% pts had >Grade 3 AEs, no differences in the safety profile were observed. Amongst patients with gain/amp 1q21, median PFS was [RVd-Elo=31 mos., RVd= 37 mos., HR = 1.48 (80% CI= 0.95, 2.31), p=0.25], median OS was [RVd-Elo = 61 mos., RVd= 68 mos., HR = 1.23 (80% CI: 0.72, 2.10), p-value = 0.63]. In patients with del(17p), median PFS was RVd-Elo=41 mos., RVd= 30 mos.[HR = 0.98 (80% CI= 0.60, 1.58), p=0.95], median OS RVd-Elo = NR, RVd= 72 mos., [HR = 0.77 (80% CI: 0.40, 1.48), p-value = 0.61]. Conclusions: In the first randomized HRMM study reported to date, the addition of Elo to RVd induction and maintenance did not improve PFS and OS with a median follow-up of 6 years. Although the median PFS for Del17p subgroup on RVd-Elo arm is higher than RVd, it did not achieve statistical significance. The PFS and OS observed for gain/amp 1q21 and del17p in the RVd control arm may serve as important benchmarks for future enrichment design HRMM clinical trials. The PFS and OS in both arms of the study exceeded the original statistical assumptions and support the role for PI/IMiD combination induction/maintenance therapy for this population. Clinical trial information: NCT01668719.

Published
2022
Full Text
View/download PDF

16. Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.

Author

Shapiro, Yael N., primary, Nadeem, Omar, additional, Yee, Andrew Jenho, additional, Laubach, Jacob, additional, Branagan, Andrew R., additional, Anderson, Kenneth Carl, additional, Mo, Clifton C., additional, Munshi, Nikhil C., additional, Ghobrial, Irene M., additional, Sperling, Adam Samuel, additional, Mesa, Michelle M., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Agyemang, Emerentia A., additional, Packer, Lisette R., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, El-Jawahri, Areej, additional, and O'Donnell, Elizabeth, additional

Published
2021
Full Text
View/download PDF

17. Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

Author

Facon, Thierry, primary, Auner, Holger W., additional, Gavriatopoulou, Maria, additional, Delimpasi, Sosana, additional, Simonova, Maryana, additional, Spicka, Ivan, additional, Pour, Luděk, additional, Dimopoulos, Meletios A., additional, Kriachok, Iryna, additional, Pylypenko, Halyna, additional, Leleu, Xavier, additional, Quach, Hang, additional, Reuben, Benjamin, additional, Dolai, Tuphan Kanti, additional, Sinha, Dinesh Kumar, additional, Garg, Mamta, additional, Stevens, Don A., additional, Shah, Jatin J., additional, Richardson, Paul G., additional, and Grosicki, Sebastian, additional

Published
2021
Full Text
View/download PDF

18. Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.

Author

Conti, Rena M., primary, McCue, Shaylene, additional, Dockter, Travis, additional, Rapkin, Bruce D., additional, Dusetzina, Stacie, additional, Bennett, Antonia Vickery, additional, Gracia, Gabriela, additional, Johnson, Michelle E., additional, Martin, Sarah A., additional, Chang, George J., additional, Richardson, Paul G., additional, Behrens, Robert J., additional, and Weiss, Elisa S., additional

Published
2021
Full Text
View/download PDF

20. Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

Author

Leleu, Xavier, primary, Mateos, Maria-Victoria, additional, Jagannath, Sundar, additional, Delimpasi, Sosana, additional, Simonova, Maryana, additional, Spicka, Ivan, additional, Pour, Luděk, additional, Kriachok, Iryna, additional, Gavriatopoulou, Maria, additional, Dimopoulos, Meletios A., additional, Pylypenko, Halyna, additional, Auner, Holger W., additional, Reuben, Benjamin, additional, Venner, Christopher P., additional, Garg, Mamta, additional, DeCastro, Andrew, additional, Shah, Jatin J., additional, Grosicki, Sebastian, additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

21. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).

Author

Richardson, Paul G., primary, Perrot, Aurore, additional, F. San-Miguel, Jesús, additional, Beksac, Meral, additional, Spicka, Ivan, additional, Leleu, Xavier, additional, Schjesvold, Fredrik, additional, Moreau, Philippe, additional, Dimopoulos, Meletios A., additional, Huang, Jeffrey SY., additional, Minarik, Jiri, additional, Cavo, Michele, additional, Prince, H. Miles, additional, Zheng, Cheng, additional, Dubin, Franck, additional, Van De Velde, Helgi, additional, and Anderson, Kenneth Carl, additional

Published
2021
Full Text
View/download PDF

22. Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.

Author

Rodríguez-Otero, Paula, primary, Mateos, Maria-Victoria, additional, Oriol, Albert, additional, Larocca, Alessandra, additional, Blade, Joan, additional, Cavo, Michele, additional, Leleu, Xavier, additional, Nadeem, Omar, additional, Hiemenz, John W., additional, Hassoun, Hani, additional, Touzeau, Cyrille, additional, Alegre, Adrian, additional, Paner, Agne, additional, Maisel, Christopher, additional, Mazumder, Amitabha, additional, Raptis, Anastasios, additional, Thuresson, Marcus, additional, Harmenberg, Johan, additional, Harlin, Olof, additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

23. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Author

Kumar, Shaji, primary, Jacobus, Susanna J., additional, Cohen, Adam D., additional, Weiss, Matthias, additional, Callander, Natalie Scott, additional, Singh, Avina A., additional, Parker, Terri L., additional, Menter, Alex R., additional, Yang, Xuezhong, additional, Parsons, Benjamin Marshall, additional, Kumar, Pankaj, additional, Kapoor, Prashant, additional, Rosenberg, Aaron Seth, additional, Zonder, Jeffrey A., additional, Faber, Edward Anthony, additional, Lonial, Sagar, additional, Richardson, Paul G., additional, Orlowski, Robert Z., additional, Wagner, Lynne I., additional, and Rajkumar, S. Vincent, additional

Published
2020
Full Text
View/download PDF

24. Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.

Author

Schjesvold, Fredrik, primary, Dimopoulos, Meletios A., additional, Beksac, Meral, additional, Oriol, Albert, additional, Lindsay, Jindriska, additional, Liberati, Anna Marina, additional, Galli, Monica, additional, Robak, Pawel, additional, Weisel, Katja, additional, Larocca, Alessandra, additional, Yagci, Münci, additional, Vural, Filiz, additional, Anderson, Jr, Larry D., additional, Kanate, Abraham Sebastian, additional, Casal Mendez, Eva, additional, Jiang, Ruiyun, additional, Srinivasan, Shankar, additional, Grote, Lara, additional, Biyukov, Tsvetan Nikolov, additional, and Richardson, Paul G., additional

Published
2020
Full Text
View/download PDF

26. HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

Author

Mateos, Maria-Victoria, primary, Oriol, Albert, additional, Larocca, Alessandra, additional, Blade, Joan, additional, Cavo, Michele, additional, Rodríguez Otero, Paula, additional, Leleu, Xavier, additional, Hiemenz, John W., additional, Hassoun, Hani, additional, Touzeau, Cyrille, additional, Alegre, Adrian, additional, Paner, Agne, additional, Maisel, Christopher, additional, Mazumder, Amitabha, additional, Raptis, Anastasios, additional, Harmenberg, Johan, additional, Zavisic, Stojan, additional, Thuresson, Sara, additional, Öhman, Oskar, additional, and Richardson, Paul G., additional

Published
2020
Full Text
View/download PDF

27. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.

Author

Lee, Hans Chulhee, primary, Cohen, Adam D., additional, Chari, Ajai, additional, Hultcrantz, Malin, additional, Nooka, Ajay K., additional, Callander, Natalie Scott, additional, Suvannasankha, Attaya, additional, Badros, Ashraf, additional, Libby, Edward N., additional, Trudel, Suzanne, additional, Richardson, Paul G., additional, Sborov, Douglas Weston, additional, Rodríguez Otero, Paula, additional, Lonial, Sagar, additional, Zhi, Eric, additional, Lewis, Eric, additional, Gupta, Ira, additional, and Opalinska, Joanna, additional

Published
2020
Full Text
View/download PDF

28. Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).

Author

Wong, Lilly, primary, Jiménez Nuñez, María Dolores, additional, Bahlis, Nizar J., additional, Vangsted, Annette J., additional, Ramasamy, Karthik, additional, Trudel, Suzanne, additional, Martínez, Joaquín, additional, Mateos, Maria-Victoria, additional, Rodríguez Otero, Paula, additional, Lonial, Sagar, additional, Popat, Rakesh, additional, Oriol, Albert, additional, Karanes, Chatchada, additional, Orlowski, Robert Z., additional, Berdeja, Jesus G., additional, Wang, Maria, additional, Lamba, Manisha, additional, Pourdehnad, Michael, additional, Pierce, Daniel W., additional, and Richardson, Paul G., additional

Published
2020
Full Text
View/download PDF

29. DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

Author

Richardson, Paul G., primary, Biswas, Swethajit, additional, Holkova, Beata, additional, Jackson, Nicola, additional, Netherway, Thelma, additional, Paul, Sofia, additional, Ferron-Brady, Geraldine, additional, Yeakey, Anne, additional, Shelton, Chris, additional, Montes de Oca, Rocio, additional, Ahlers, Christoph Matthias, additional, Ballas, Marc S., additional, Paul, Elaine Marie, additional, Gupta, Ira, additional, Opalinska, Joanna, additional, and Luptakova, Katarina, additional

Published
2020
Full Text
View/download PDF

30. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.

Author

Cohen, Adam D., primary, Trudel, Suzanne, additional, Lonial, Sagar, additional, Libby, Edward N., additional, Lee, Hans Chulhee, additional, Besemer, Britta, additional, Facon, Thierry, additional, Nooka, Ajay K., additional, Callander, Natalie Scott, additional, Chari, Ajai, additional, Gupta, Ira, additional, Paul, Sofia, additional, Opalinska, Joanna, additional, and Richardson, Paul G., additional

Published
2020
Full Text
View/download PDF

31. Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma.

Author

Chauhan, Dharminder, primary, Ray, Arghya, additional, Song, Yan, additional, Olguin, Arturo, additional, Chen, Janice, additional, Brooks, Christopher, additional, Mughal, Tariq I., additional, Richardson, Paul G., additional, and Anderson, Kenneth Carl, additional

Published
2020
Full Text
View/download PDF

32. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

Author

Dimopoulos, Meletios A., primary, Delimpasi, Sosana, additional, Simonova, Maryana, additional, Spicka, Ivan, additional, Pour, Ludek, additional, Kryachok, Iryna, additional, Gavriatopoulou, Maria, additional, Pylypenko, Halyna, additional, Auner, Holger W, additional, Leleu, Xavier, additional, Doronin, Vadim, additional, Kaplan, Polina, additional, Hajek, Roman, additional, Reuben, Benjamin, additional, Dolai, Tuphan Kanti, additional, Sinha, Dinesh Kumar, additional, Arazy, Melina, additional, Richardson, Paul G., additional, Bahlis, Nizar J., additional, and Grosicki, Sebastian, additional

Published
2020
Full Text
View/download PDF

33. First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Author

Richardson, Paul G., primary, Vangsted, Annette J., additional, Ramasamy, Karthik, additional, Trudel, Suzanne, additional, Martínez, Joaquín, additional, Mateos, Maria-Victoria, additional, Rodríguez Otero, Paula, additional, Lonial, Sagar, additional, Popat, Rakesh, additional, Oriol, Albert, additional, Karanes, Chatchada, additional, Orlowski, Robert Z., additional, Berdeja, Jesus G., additional, Wong, Lilly, additional, Shi, Chenyang, additional, Lamba, Manisha, additional, Barnett, Evelyn, additional, Pierce, Daniel W., additional, Pourdehnad, Michael, additional, and Bahlis, Nizar J., additional

Published
2020
Full Text
View/download PDF

34. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Author

Usmani, Saad Zafar, primary, Ailawadhi, Sikander, additional, Sexton, Rachael, additional, Hoering, Antje, additional, Lipe, Brea, additional, Hita, Sandi, additional, Durie, Brian G., additional, Zonder, Jeffrey A., additional, Dhodapkar, Madhav V., additional, Callander, Natalie Scott, additional, Rajkumar, S. Vincent, additional, Voorhees, Peter Michael, additional, Richardson, Paul G., additional, and Orlowski, Robert Z., additional

Published
2020
Full Text
View/download PDF

35. Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Author

Richardson, Paul G., primary, Jagannath, Sundar, additional, Chari, Ajai, additional, Vogl, Dan T., additional, Dimopoulos, Meletios A., additional, Moreau, Philippe, additional, Dingli, David, additional, Wei, L J, additional, Li, Lingling, additional, Tang, Shijie, additional, Reichman, William, additional, Kauffman, Michael G., additional, Shah, Jatin J., additional, Shacham, Sharon, additional, and Lonial, Sagar, additional

Published
2019
Full Text
View/download PDF

36. Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Author

Bringhen, Sara, primary, Richardson, Paul G., additional, Voorhees, Peter Michael, additional, Plesner, Torben, additional, Mellqvist, Ulf-Henrik, additional, Zonder, Jeffrey A., additional, Reeves, Brandi Nikcole, additional, Zavisic, Stojan, additional, Harmenberg, Johan, additional, Obermüller, Jakob, additional, and Sonneveld, Pieter, additional

Published
2019
Full Text
View/download PDF

37. A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Author

Yee, Andrew Jenho, primary, Laubach, Jacob, additional, Campagnaro, Erica Leigh, additional, Lipe, Brea, additional, Nadeem, Omar, additional, Cole, Craig, additional, O'Donnell, Elizabeth, additional, Schlossman, Robert L., additional, Bianchi, Giada, additional, Branagan, Andrew Robert, additional, Shapiro, Samantha J., additional, Harrington, Cynthia C., additional, Burke, Jill N., additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Thorburn, Cassandra Ann, additional, Mann, Mason L., additional, Lohr, Jens Guenter, additional, Richardson, Paul G., additional, and Raje, Noopur S., additional

Published
2018
Full Text
View/download PDF

38. Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Author

Lonial, Sagar, primary, Dimopoulos, Meletios A., additional, Weisel, Katja, additional, White, Darrell, additional, Moreau, Philippe, additional, Mateos, Maria-Victoria, additional, San-Miguel, Jesus, additional, Anderson, Kenneth Carl, additional, Shpilberg, Ofer, additional, Grosicki, Sebastian, additional, Spicka, Ivan, additional, Walter-Croneck, Adam, additional, Magen, Hila, additional, Belch, Andrew, additional, Reece, Donna Ellen, additional, Beksac, Meral, additional, Shelat, Suresh, additional, Sy, Oumar, additional, Singhal, Anil K., additional, and Richardson, Paul G., additional

Published
2018
Full Text
View/download PDF

40. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Author

McCarthy, Philip L., primary, Holstein, Sarah A., additional, Petrucci, Maria Teresa, additional, Richardson, Paul G., additional, Hulin, Cyrille, additional, Tosi, Patrizia, additional, Bringhen, Sara, additional, Musto, Pellegrino, additional, Anderson, Kenneth C., additional, Caillot, Denis, additional, Gay, Francesca, additional, Moreau, Philippe, additional, Marit, Gerald, additional, Jung, Sin-Ho, additional, Yu, Zhinuan, additional, Winograd, Benjamin, additional, Knight, Robert D., additional, Palumbo, Antonio, additional, and Attal, Michel, additional

Published
2017
Full Text
View/download PDF

42. Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data.

Author

Kernan, Nancy A., primary, Richardson, Paul G., additional, Triplett, Brandon, additional, Grupp, Stephan A., additional, Antin, Joseph Harry, additional, Messinger, Yoav H., additional, Liang, Wei, additional, Hume, Robin, additional, Tappe, William, additional, and Soiffer, Robert, additional

Published
2017
Full Text
View/download PDF

43. Timing of initiation of defibrotide (DF) post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final data from an expanded-access protocol.

Author

Grupp, Stephan A., primary, Richardson, Paul G., additional, Smith, Angela R., additional, Triplett, Brandon, additional, Kernan, Nancy A., additional, Antin, Joseph Harry, additional, Lehmann, Leslie, additional, Giralt, Sergio, additional, Liang, Wei, additional, Hume, Robin, additional, Tappe, William, additional, and Soiffer, Robert, additional

Published
2017
Full Text
View/download PDF

44. CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma—Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO).

Author

McCarthy, Philip L., primary, Holstein, Sarah A., additional, Jung, Sin-Ho, additional, Cooper, Miranda, additional, Gibson, Craig J, additional, Stadtmauer, Edward Allen, additional, Winograd, Benjamin, additional, and Richardson, Paul G., additional

Published
2017
Full Text
View/download PDF

45. Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial.

Author

Denninger, John W., primary, Laubach, Jacob P., additional, Yee, Andrew Jenho, additional, O'Donnell, Elizabeth, additional, Macklin, Eric A., additional, Perez, Giselle Katiria, additional, Traeger, Lara N., additional, Chad-Friedman, Emma, additional, Proszynski, Jacqueline, additional, Jacquart, Jolene, additional, Goldman, Roberta, additional, Riklin, Eric, additional, Niles, Halsey, additional, Nehrt, Emily M., additional, Chaukos, Deanna C., additional, Richardson, Paul G., additional, Raje, Noopur S., additional, Fricchione, Gregory L., additional, Park, Elyse R., additional, and Benson, Herbert, additional

Published
2017
Full Text
View/download PDF

47. Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).

Author

Bahlis, Nizar J., primary, Moreau, Philippe, additional, Nahi, Hareth, additional, Plesner, Torben, additional, Goldschmidt, Hartmut, additional, Suzuki, Kenshi, additional, Orlowski, Robert Z., additional, Rabin, Neil, additional, Leiba, Merav, additional, Oriol, Albert, additional, Chari, Ajai, additional, San Miguel, Jesus, additional, Richardson, Paul G., additional, Usmani, Saad Zafar, additional, O'Rourke, Lisa Marie, additional, Wu, Kaida, additional, Casneuf, Tineke, additional, Chiu, Christopher, additional, Qin, Xiang, additional, and Dimopoulos, Meletios A., additional

Published
2017
Full Text
View/download PDF

48. An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.

Author

Laubach, Jacob, primary, Nooka, Ajay K., additional, Cole, Craig, additional, O'Donnell, Elizabeth, additional, Vij, Ravi, additional, Usmani, Saad Zafar, additional, Orloff, Gregory Joshua, additional, Richter, Joshua Ryan, additional, Redd, Robert, additional, DiPietro, Heidi, additional, Cummings, Kristen, additional, Hansen, Joshua, additional, Henrick, Patrick M., additional, Bassett, Paul, additional, Schachter, Haley, additional, Richardson, Paul G., additional, and Lonial, Sagar, additional

Published
2017
Full Text
View/download PDF

49. Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

Author

Richardson, Paul G., primary, Bensinger, William, additional, Weisel, Katja C., additional, Boyd, Kevin, additional, Ramasamy, Karthik, additional, Gonzalez, Esther, additional, Favre-Kontula, Linda, additional, Peluso, Teresa, additional, Sternas, Lars Axel, additional, Di Casoli, Carl, additional, Zaki, Mohamed H., additional, and Facon, Thierry, additional

Published
2017
Full Text
View/download PDF

50. Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Author

Lonial, Sagar, primary, Dimopoulos, Meletios A., additional, Weisel, Katja C., additional, White, Darrell, additional, Moreau, Philippe, additional, Mateos, Maria-Victoria, additional, San Miguel, Jesus, additional, Anderson, Kenneth Carl, additional, Shpilberg, Ofer, additional, Grosicki, Sebastian, additional, Spicka, Ivan, additional, Walter-Croneck, Adam, additional, Magen, Hila, additional, Belch, Andrew, additional, Reece, Donna Ellen, additional, Beksac, Meral, additional, Mekan, Sabeen, additional, Sy, Oumar, additional, Singhal, Anil K., additional, and Richardson, Paul G., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results